陕西地区丙肝患者分型与疗效分析
|
摘要
目的对陕西省内三家大型医院就诊丙肝患者做丙肝基因分型,并对分型结果做实验指标与疗效分析,以期发现其中的变化规律.方法对就诊437例丙肝阳性患者中的253例丙肝分型阳性患者做实验指标和病情分析.结果各型丙肝肝功能实验其中4项指标、胆汁酸受体I含量和丙肝基因含量差异有统计学意义(P<0.05);丙肝不同亚型聚乙二醇干扰素加利巴韦林治疗后疗效,差异无统计学意义(P>0.05),但治愈率和好转率各型差异有统计学意义(P<0.05).结论陕西省内丙肝患者以Ib型和Ⅱa型为主,肝功能4项指标、丙肝基因含量和胆汁酸受体I含量在病情严重程度判断与治疗上有重要意义.3 b、3 a和6 a型治愈率和好转率较高,1 b、1a和2 a型治愈率和好转率较低.口服药物对丙肝治疗效果提高.
Objective To study the genotypes of hepatitis C patients in three large hospitals in Shanxi Province, and to analyze the results of the classification. Methods Genotypes and related disease markers of253 cases of hepatitis C positive patients in a total of 437 cases were analyzed.Results There was a significant difference in the I content of each type of bile acid receptor and HCV gene content among all HCV Classification patients(P<0.05) while there was no significant difference in the therapeutic effects of pegylated interferon and Galebavirin in different subtypes of HCV(P>0.05). Conclusions Hepatitis C patients in Shanxi province are mainly type Ib and type II A, and there are significant differences in each type of gene content(P<0.05). The content of I of bile acid receptor is of great significance in the judgement and treatment of the disease.Type 3 b,type 3 a and type 6 a have higher cure rates and better recovery rates, while type1 b, type 1 a and type 2 a have lower cure rates and recovery rates.The use of oral drugs makes hepatitis C treatment better.
Objective To study the genotypes of hepatitis C patients in three large hospitals in Shanxi Province, and to analyze the results of the classification. Methods Genotypes and related disease markers of253 cases of hepatitis C positive patients in a total of 437 cases were analyzed.Results There was a significant difference in the I content of each type of bile acid receptor and HCV gene content among all HCV Classification patients(P<0.05) while there was no significant difference in the therapeutic effects of pegylated interferon and Galebavirin in different subtypes of HCV(P>0.05). Conclusions Hepatitis C patients in Shanxi province are mainly type Ib and type II A, and there are significant differences in each type of gene content(P<0.05). The content of I of bile acid receptor is of great significance in the judgement and treatment of the disease.Type 3 b,type 3 a and type 6 a have higher cure rates and better recovery rates, while type1 b, type 1 a and type 2 a have lower cure rates and recovery rates.The use of oral drugs makes hepatitis C treatment better.
引文
[1]甘雪梅,李武.丙型肝炎治疗的机遇与挑战[J].昆明医科大学学报,2014,35(12):1-3.
[2]李莹,张淑琼,俞建昆,等.云南汉族人群IL-10基因启动子多态性与HCV慢性感染的相关性研究[J].昆明医科大学学报,2015,36(1):15-18.
[3]中华医学会肝病学分会,中华医学会感染病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62.
[4]付汉东,张爱华,胡校云,等.孝感地区丙型肝炎病毒基因分型特点与临床意义[J].中华医院感染学杂志,2016,26(20):4605-4607.
[5]林江,温先勇,唐敏.川南地区丙型肝炎基因型的特征及其临床价值[J].四川医学,2016,37(12):1348-1351.
[6]刘涛,陈兆云,张朝霞.新疆地区维族与汉族丙型肝炎患者HCV基因分型研究[J].中华医院感染学杂志,2015,25(18):4122-4124.
[7]胡大山,赵伟,薛蓉,等.南京与广东两地丙型肝炎215例基因分型与感染途径分析[J].江苏医药,2014,40(5):597-598.
[8]中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南[J].中华肝脏病杂志,2015,23(12):906-923.
[9]尚明金,李连友,李连兴.赤峰地区丙肝基因分型及其临床意义分析[J].中国卫生标准管理杂志,2017,8(8):3-4.
[10]谢知兵,周建亮,李勇忠,等.怀化地区丙肝基因分型分布及临床意义[J].中国现代医学杂志,2013,23(11):43-46.
[11]龚卫锋,张养民,张砚敏.妇科肿瘤患者血清人G蛋白胆汁酸受体1水平变化及其相关性探讨[J].陕西医学杂志,2017,46(9):1312-1313.
[12]杨永锐,李晖,沈凌.聚乙二醇干扰素ɑ-2a加利巴韦林治疗慢性丙型肝炎的临床观察[J].昆明医科大学学报,2014,35(2):100-104.
[13]许惠玲.标准化治疗方案联合辛伐他丁治疗慢性丙型肝炎的疗效分型[J].昆明医科大学学报,2015,36(4):137-139.
[14]杨永锐,李晖,沈凌,等.失代偿期丙肝肝硬化患者并发症消除后的抗病毒治疗[J].昆明医科大学学报,2014,35(1):56-67.
[15]陈国凤.DAAs时代丙肝治疗的问题与挑战[J].医学研究杂志,2016,45(4):1-7.
[16]任姗,陈新月.丙型肝炎相关直接抗病毒药物耐药的研究现状[J].临床肝胆病杂志,2015,31(11):1807-1812.
[17]张玉,徐小元.直接抗病毒药物耐药与预存耐药的研究[J].中华医学杂志,2015,95(31):2569-2571.
[18]周辛波.全球抗丙肝药物市场纵观[J].临床药物治疗杂志,2015,13(6):91.
[2]李莹,张淑琼,俞建昆,等.云南汉族人群IL-10基因启动子多态性与HCV慢性感染的相关性研究[J].昆明医科大学学报,2015,36(1):15-18.
[3]中华医学会肝病学分会,中华医学会感染病学分会.病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62.
[4]付汉东,张爱华,胡校云,等.孝感地区丙型肝炎病毒基因分型特点与临床意义[J].中华医院感染学杂志,2016,26(20):4605-4607.
[5]林江,温先勇,唐敏.川南地区丙型肝炎基因型的特征及其临床价值[J].四川医学,2016,37(12):1348-1351.
[6]刘涛,陈兆云,张朝霞.新疆地区维族与汉族丙型肝炎患者HCV基因分型研究[J].中华医院感染学杂志,2015,25(18):4122-4124.
[7]胡大山,赵伟,薛蓉,等.南京与广东两地丙型肝炎215例基因分型与感染途径分析[J].江苏医药,2014,40(5):597-598.
[8]中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南[J].中华肝脏病杂志,2015,23(12):906-923.
[9]尚明金,李连友,李连兴.赤峰地区丙肝基因分型及其临床意义分析[J].中国卫生标准管理杂志,2017,8(8):3-4.
[10]谢知兵,周建亮,李勇忠,等.怀化地区丙肝基因分型分布及临床意义[J].中国现代医学杂志,2013,23(11):43-46.
[11]龚卫锋,张养民,张砚敏.妇科肿瘤患者血清人G蛋白胆汁酸受体1水平变化及其相关性探讨[J].陕西医学杂志,2017,46(9):1312-1313.
[12]杨永锐,李晖,沈凌.聚乙二醇干扰素ɑ-2a加利巴韦林治疗慢性丙型肝炎的临床观察[J].昆明医科大学学报,2014,35(2):100-104.
[13]许惠玲.标准化治疗方案联合辛伐他丁治疗慢性丙型肝炎的疗效分型[J].昆明医科大学学报,2015,36(4):137-139.
[14]杨永锐,李晖,沈凌,等.失代偿期丙肝肝硬化患者并发症消除后的抗病毒治疗[J].昆明医科大学学报,2014,35(1):56-67.
[15]陈国凤.DAAs时代丙肝治疗的问题与挑战[J].医学研究杂志,2016,45(4):1-7.
[16]任姗,陈新月.丙型肝炎相关直接抗病毒药物耐药的研究现状[J].临床肝胆病杂志,2015,31(11):1807-1812.
[17]张玉,徐小元.直接抗病毒药物耐药与预存耐药的研究[J].中华医学杂志,2015,95(31):2569-2571.
[18]周辛波.全球抗丙肝药物市场纵观[J].临床药物治疗杂志,2015,13(6):91.